New schizophrenia drug NS-136 enters Mid-Stage trial
NCT ID NCT07521683
First seen Apr 22, 2026 · Last updated Apr 26, 2026 · Updated 1 time
Summary
This study tests a new medicine called NS-136 to see if it can help reduce symptoms of schizophrenia. About 150 adults with acute schizophrenia will receive either a low dose, a high dose, or a placebo pill daily for 5 weeks. Researchers will measure changes in symptom scores and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA(ACUTE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NeuShen
Shanghai, China
Conditions
Explore the condition pages connected to this study.